BiVACOR is a preclinical stage medical device company developing the BiVACOR Total Artificial Heart (TAH), the first long-term therapy for patients with severe heart failure. The TAH is designed to replace the complete function of the native heart and address the global unmet need of patients with end-stage heart failure (HF) by providing a life-extending solution.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/20/21 | $19,000,000 | Series B |
Cormorant Asset Management OneVentures | undisclosed |
